FDA
Nelkarmi is one of two bounties from GSK’s $10.6 billion acquisition of Nuvalent Bio—the other being the ROS1 inhibitor zidesamtinib, which won FDA approval earlier this year as Jideytro.
Summit Therapeutics was warned twice by the FDA that the Phase 3 trial used to support the application for ivonescimab did not include patients that accurately represented the American population.
The FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech history; ObesityWeek and Clinical Trials on Alzheimer’s Disease conferences in full swing.
The Trump administration withdrew the nomination of Heidi Overton for FDA commissioner Tuesday evening, reportedly due to opposition from Republican Senators.
Analysts are broadly confident that povetacicept will notch an approval in IgA nephropathy by the end of the month, setting up “the next wave” for Vertex Pharmaceuticals.
The FDA rejected Summit Therapeutics’ ivonescimab over the weekend, sending a strong message to rival drugmakers Bristol Myers Squibb, BioNTech, Pfizer, Merck and AbbVie.
Companies at BIO-Europe said shifting U.S. politics have created an opening to promote Canada’s strengths to European partners.
The FDA has denied an approval for Summit Therapeutics’ ivonescimab to treat EGFR-mutated non-small cell lung cancer, blocking the drug’s entry to the U.S. after it became available in China in 2024.
BioSpace reviews upcoming cardiovascular milestones after a summer of missed targets.
In advance of a Senate vote on Heidi Overton as the next FDA commissioner, the agency has shelved the Commissioner’s National Priority Voucher program introduced by former leader Marty Makary, Reuters reported Thursday.
PRESS RELEASES